Prostate Cancer Market Outlook

Thelansis’s “Prostate Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Prostate Cancer Overview

Prostate cancer is the most common malignancy in men, arising from prostatic glandular epithelium driven by androgen receptor signalling, with somatic alterations in PTEN, TP53, RB1, and DNA repair genes including BRCA1, BRCA2, and CDK12 underpinning aggressive and castration-resistant disease biology. Patients present with urinary symptoms, elevated PSA, or incidentally detected nodules, with many diagnosed through PSA-based screening programmes; multiparametric MRI and targeted biopsy have refined diagnostic precision, while PSMA PET-CT represents the current standard for sensitive metastatic staging. Gleason grading and clinical staging guide risk stratification and therapeutic intensity. Localised disease is managed with active surveillance in low-risk disease, radical prostatectomy, or radiotherapy with or without androgen deprivation therapy. Metastatic hormone-sensitive disease is addressed with androgen deprivation therapy combined with novel androgen receptor pathway inhibitors including enzalutamide, apalutamide, or darolutamide, or docetaxel in high-volume disease. Castration-resistant prostate cancer is managed with enzalutamide, abiraterone, cabazitaxel, or radium-223 for bone-predominant disease. PARP inhibitors olaparib and rucaparib address homologous recombination repair-deficient disease, while pembrolizumab targets MSI-H or TMB-high tumours. Lutetium-177 PSMA-617 represents a transformative radioligand therapy for PSMA-positive metastatic castration-resistant disease. Prognosis varies considerably with stage and molecular features; multidisciplinary management, bone health optimisation, and patient-centred quality-of-life considerations are integral to long-term care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)